204 related articles for article (PubMed ID: 19908318)
21. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Jung HA; Maeng CH; Park S; Kim SJ; Kim K; Jang JH; Jung CW
Anticancer Res; 2014 Feb; 34(2):1037-45. PubMed ID: 24511052
[TBL] [Abstract][Full Text] [Related]
22. Core-binding factor acute myeloid leukemia.
Sangle NA; Perkins SL
Arch Pathol Lab Med; 2011 Nov; 135(11):1504-9. PubMed ID: 22032582
[TBL] [Abstract][Full Text] [Related]
23. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
Marcucci G; Caligiuri MA; Bloomfield CD
Cancer Invest; 2000; 18(8):768-80. PubMed ID: 11107447
[TBL] [Abstract][Full Text] [Related]
24. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
25. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
26. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; von Neuhoff C; Sander A; Schrauder A; Teigler-Schlegel A; Stary J; Corbacioglu S; Reinhardt D
Blood; 2011 Nov; 118(20):5409-15. PubMed ID: 21948298
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
28. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia (AML-M1) with multiple trisomies and t(8;21)(q22;q22).
Köhler M; Johansson B; Ludvigsson J; Aman P; Heim S; Mitelman F
Cancer Genet Cytogenet; 1994 Mar; 73(1):79-81. PubMed ID: 8174079
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
31. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
Ustun C; Marcucci G
Curr Opin Hematol; 2015 Mar; 22(2):85-91. PubMed ID: 25635758
[TBL] [Abstract][Full Text] [Related]
32. A rare cytogenetic presentation of acute myeloid leukemia (AML-M2).
Kumari P; LingappaKavitha B; Obula Reddy C; Mangalagowri M; Madhumathi DS; Mahadeva Prasad M; Raghavendra HV; Premalata CS; Lakshmaiah KC; Mir Mazloumi SH
Acta Med Iran; 2012; 50(12):827-30. PubMed ID: 23456526
[TBL] [Abstract][Full Text] [Related]
33. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Haferlach T; Kohlmann A; Klein HU; Ruckert C; Dugas M; Williams PM; Kern W; Schnittger S; Bacher U; Löffler H; Haferlach C
Leukemia; 2009 May; 23(5):934-43. PubMed ID: 19194466
[TBL] [Abstract][Full Text] [Related]
34. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
35. Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N; Terzer T; Sträng E; Dolnik A; Cocciardi S; Panina E; Corbacioglu A; Herzig J; Weber D; Schrade A; Götze K; Schröder T; Lübbert M; Wellnitz D; Koller E; Schlenk RF; Gaidzik VI; Paschka P; Rücker FG; Heuser M; Thol F; Ganser A; Benner A; Döhner H; Bullinger L; Döhner K
Blood Adv; 2020 Dec; 4(24):6342-6352. PubMed ID: 33351131
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H; Shajiei A; Sadeghian MH; Sheikhi M; Yazdandoust E; Ghazanfarpour M; Shams SF; Shakeri S
Hematol Oncol Stem Cell Ther; 2017 Mar; 10(1):1-7. PubMed ID: 27613372
[TBL] [Abstract][Full Text] [Related]
37. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
38. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia.
Hsiao HH; Liu YC; Wang HC; Tsai YF; Wu CH; Cho SF; Hsu JF; Huang CT; Hsiao SY; Lee CP; Chang CS; Lin SF; Liu TC
Genet Mol Res; 2015 Dec; 14(4):17028-33. PubMed ID: 26681050
[TBL] [Abstract][Full Text] [Related]
39. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).
Han SY; Mrózek K; Voutsinas J; Wu Q; Morgan EA; Vestergaard H; Ohgami R; Kluin PM; Kristensen TK; Pullarkat S; Møller MB; Schiefer AI; Baughn LB; Kim Y; Czuchlewski D; Hilberink JR; Horny HP; George TI; Dolan M; Ku NK; Arana Yi C; Pullarkat V; Kohlschmidt J; Salhotra A; Soma L; Bloomfield CD; Chen D; Sperr WR; Marcucci G; Cho C; Akin C; Gotlib J; Broesby-Olsen S; Larson M; Linden MA; Deeg HJ; Hoermann G; Perales MA; Hornick JL; Litzow MR; Nakamura R; Weisdorf D; Borthakur G; Huls G; Valent P; Ustun C; Yeung CCS
Blood Adv; 2021 May; 5(10):2481-2489. PubMed ID: 34003250
[TBL] [Abstract][Full Text] [Related]
40. CD7+ near-tetraploid acute myeloblastic leukemia M2 with double t(8;21)(q22;q22) translocations and Aml1/ETO rearrangements detected by fluorescence in situ hybridization analysis.
Yamamoto K; Nagata K; Kida A; Tsurukubo Y; Hamaguchi H
Int J Hematol; 2001 Oct; 74(3):316-21. PubMed ID: 11721969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
